SEC Comment Letter for INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Mar 23, 2020
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: March 23, 2020 · CIK: 0001055726 · Accession: 0000000000-20-002492
AI Filing Summary & Sentiment
File numbers found in text: 333-237172
Letter
March 20, 2020 J. Joseph Kim, Ph.D. President and Chief Executive Officer Inovio Pharmaceuticals, Inc. 660 West Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 Re:Inovio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237172 Dear Dr. Kim: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Darah Protas, Esq.
Show Raw Text
March 20, 2020
J. Joseph Kim, Ph.D.
President and Chief Executive Officer
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
Re:Inovio Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237172
Dear Dr. Kim:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Darah Protas, Esq.